EOLE - Observational study of Long-term follow-up of post-myocardial infarction

Head :Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen Blin Patrick, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Last update: 10/26/2017 | Version: 2 | ID: 2818

Last update : 10/26/2017 Version : 2 ID	: 2818
General	
Identification	
Detailed name	Observational study of Long-term follow-up of post-myocardial infarction
Sign or acronym	EOLE
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CCTIRS 05.484, CNIL 906042
General Aspects	
Medical area	Cardiology
Health determinants	Lifestyle and behavior Medicine Nutrition Occupation
Keywords	Acute Myocardial Infarction (AMI), lifestyle and dietary recommendations, cardiovascular treatments, secondary prevention, mortality, pharmacoepidemiology, cohort, Department of Pharmacology, Bordeaux
Scientific investigator(s) (Contact)	
Name of the director	Moore
Surname	Nicholas

Surname	Nicholas
Address	Bât du Tondu - Case 41- 146, Rue Léo Saignat - 33076 BORDEAUX Cedex
Phone	+ 33 (0)5 57 57 46 75
Email	nicholas.moore@u-bordeaux2.fr

Unit Service de Pharmacologie, CIC-P 0005-INSERM

U657- Université Bordeaux Segalen

Organization Université Bordeaux

Name of the director Blin

Surname Patrick

Address Bât du Tondu - Case 41- 146, Rue Léo Saignat -

33076 BORDEAUX Cedex

Phone + 33 (0)5 57 57 46 75

Email patrick.blin@pharmaco.u-bordeaux2.fr

Unit Service de Pharmacologie, CIC-P 0005-INSERM

U657- Université Bordeaux Segalen

Organization Université Bordeaux

Collaborations

Participation in projects, networks and consortia

No

Funding

Funding status Private

Details Pierre Fabre Médicament (unconditional support)

Governance of the database

Sponsor(s) or organisation(s)

responsible

Service de Pharmacologie, CIC-P 0005-INSERM

U657- Université Bordeaux Segalen

Organisation status Public

Presence of scientific or steering committees

Yes

Additional contact

Main features

Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary	A selection of health care professionals
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Patients are included by cardiologists who are themselves selected from a random sample of hospital and non-hospital cardiologists in metropolitan France.
Database objective	
Main objective	The main objective is to assess in real situations of use the impact of cardiovascular medications and recommended lifestyle and dietary recommendations on all-cause mortality in secondary prevention of myocardial infarction.
Inclusion criteria	Patient with recent (?3 months) acute myocardial infarction (first or recurrent heart attack); Patient seen during the first or second consultation after acute myocardial infarction; Infarct defined by the presence at least of two among the following criteria: symptomatic (characteristic pain), electric (Q wave and / or ST elevation in at least two adjacent leads), enzymatic (elevated CPKMB and / or troponin greater than 2 twice the normal value); Patient who may be followed for 6 years; Patient without a non-cardiovascular disease that is lifethreatening in the short term (?3 months); Patient not included in a clinical trial of an non marketed drug; Patient not affected by a language barrier (unable to read the information sheet or complete the self-administered questionnaires); Patient agreeing to participate.
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	National

Detail of the geography area	Hospital and non-hospital cardiologists in metropolitan France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2006
Date of last collection (YYYY or MM/YYYY)	2015
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	5538
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Declarative data Administrative data
Clinical data (detail)	Direct physical measures
Declarative data (detail)	Paper self-questionnaire Internet self-questionnaire Phone interview
Details of collected declarative data	Questionnaire diet, physical activity before and after myocardial infarction, tobacco use, drugs taken, and hospitalisations after myocardial infarction of inclusion
Administrative data (detail)	Patient name, first name, date and place of birth, phone number and address, contact details of the general practitioner.
Presence of a biobank	No
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services Quality of life/health perception

Care consumption (detail) Hospitalization Medicines consumption

Procedures Data collection method		•
patients via a paper question/naire. Follo-up data are collected by cardiologists (only at 6 and 24 months of follow up in the first includion period) and by patients via an eCRF or a paper questionnaire. Participant monitoring Yes Monitoring procedures Monitoring by contact with the participant (mail, email, telephone etc.) Details on monitoring of participants The total follow-up is 6 years with an evaluation at 6 months, 24 months, 3 years 4 years 5 years 6 years via a self-administered questionnaire. Patients may fill-out these questionnaire is via the internet (eCRF) or by postal mail using a paper questionnaire. The data collected in this questionnaire concern dietary habits since the AMI (only at 6 and 24 months of follow-up for patients included during the first inclusion period), treatments taken, physical activity, smoking, current health status, and hospitalizations. Follow-up by cardiologists concerns only patients included in the first inclusion period with an evaluation at 6 and 24 months (vital status, cardiovascular events, clinical and laboratory data, prescribed cardiovascular treatments). Vital status determination of included patients at 3.5 years and 6 years will be performed using the INSERM / INSEE procedure. Links to administrative sources Yes Linked administrative sources RNIPP, CéPIDC List of publications in HAL Access Terms of data access (charter for data provision, format of data, availability delay) Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications	Procedures	
Monitoring procedures Monitoring by contact with the participant (mail, email, telephone etc.) Details on monitoring of participants The total follow-up is 6 years with an evaluation at 6 months, 24 months, 3 years 4 years 5 years 6 years via a self-administered questionnaire. Patients may fill-out these questionnaire via the internet (eCRF) or by postal mail using a paper questionnaire. The data collected in this questionnaire concern dietary habits since the AMI (only at 6 and 24 months of follow-up for patients included during the first inclusion period), treatments taken, physical activity, smoking, current health status, and hospitalizations. Follow-up by cardiologists concerns only patients included in the first inclusion period with an evaluation at 6 and 24 months (vital status, cardiovascular events, clinical and laboratory data, prescribed cardiovascular treatments). Vital status determination of included patients at 3.5 years and 6 years will be performed using the INSERM / INSEE procedure. Links to administrative sources Yes Linked administrative sources (detail) Promotion Link to the document http://www.hal.inserm.fr/EOLE/ List of publications in HAL Access Terms of data access (charter for data provision, format of data, availability delay) Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications	Data collection method	patients via a paper questionnaire. Follo-up data are collected by cardiologists (only at 6 and 24 months of follow up in the first includion period) and by
Details on monitoring of participants The total follow-up is 6 years with an evaluation at 6 months, 24 months, 3 years 4 years 5 years 6 years will-out these questionnaire. Patients may fill-out these questionnaires via the internet (eCRF) or by postal mail using a paper questionnaire. The data collected in this questionnaire concern dietary habits since the AMI (only at 6 and 24 months of follow-up for patients included during the first inclusion period), treatments taken, physical activity, smoking, current health status, and hospitalizations. Follow-up by cardiologists concerns only patients included in the first inclusion period with an evaluation at 6 and 24 months (vital status, cardiovascular events, clinical and laboratory data, prescribed cardiovascular treatments). Vital status determination of included patients at 3.5 years and 6 years will be performed using the INSERM / INSEE procedure. Links to administrative sources Links to administrative sources (detail) Promotion Link to the document http://www.hal.inserm.fr/EOLE/ Description Link to the data access (charter for data provision, format of data, availability delay) Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications	Participant monitoring	Yes
months, 24 months, 3 years 4 years 5 years 6 years via a self-administered questionnaire. Patients may fill-out these questionnaires via the internet (eCRF) or by postal mail using a paper questionnaire. The data collected in this questionnaire concern dietary habits since the AMI (only at 6 and 24 months of follow-up for patients included during the first inclusion period), treatments taken, physical activity, smoking, current health status, and hospitalizations. Follow-up by cardiologists concerns only patients included in the first inclusion period with an evaluation at 6 and 24 months (vital status, cardiovascular events, clinical and laboratory data, prescribed cardiovascular treatments). Vital status determination of included patients at 3.5 years and 6 years will be performed using the INSERM / INSEE procedure. Links to administrative sources (detail) Promotion Link to the document http://www.hal.inserm.fr/EOLE/ List of publications in HAL Access Terms of data access (charter for data provision, format of data, availability delay) Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications	Monitoring procedures	
Linked administrative sources (detail) Promotion and access Promotion Link to the document Description List of publications in HAL Access Terms of data access (charter for data provision, format of data, availability delay) RNIPP, CéPIDC RNIPP, CéPIDC List of publications in HAL Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications		months, 24 months, 3 years 4 years 5 years 6 years via a self-administered questionnaire. Patients may fill-out these questionnaires via the internet (eCRF) or by postal mail using a paper questionnaire. The data collected in this questionnaire concern dietary habits since the AMI (only at 6 and 24 months of follow-up for patients included during the first inclusion period), treatments taken, physical activity, smoking, current health status, and hospitalizations. Follow-up by cardiologists concerns only patients included in the first inclusion period with an evaluation at 6 and 24 months (vital status, cardiovascular events, clinical and laboratory data, prescribed cardiovascular treatments). Vital status determination of included patients at 3.5 years and 6 years will be performed using the INSERM / INSEE
Promotion and access Promotion Link to the document http://www.hal.inserm.fr/EOLE/ Description List of publications in HAL Access Terms of data access (charter for data provision, format of data, availability delay) Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications	Links to administrative sources	Yes
Promotion Link to the document http://www.hal.inserm.fr/EOLE/ Description List of publications in HAL Access Terms of data access (charter for data provision, format of data, availability delay) Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications		RNIPP, CéPIDC
Link to the document http://www.hal.inserm.fr/EOLE/ Description List of publications in HAL Access Terms of data access (charter for data provision, format of data, availability delay) Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications	Promotion and access	
Description List of publications in HAL Access Terms of data access (charter for data provision, format of data, availability delay) List of publications in HAL Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications	Promotion	
Access Terms of data access (charter for data provision, format of data, availability delay) Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications	Link to the document	http://www.hal.inserm.fr/EOLE/
Terms of data access (charter for data provision, format of data, availability delay) Confidential study reports are submitted to the Pharmaceutical company and health authorities. The study reports and scientific communications	Description	List of publications in HAL
for data provision, format of data, availability delay) Pharmaceutical company and health authorities. The study reports and scientific communications	Access	
	for data provision, format of	Pharmaceutical company and health authorities. The study reports and scientific communications

	Scientific Committee. Ownership of study data is the subject of an agreement between the University Bordeaux Segalen and the pharmaceutical company. Terms for third-party access to the database are to be defined.
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only